Healthcare Business Review: Illumina Wins Last LAWSUIT, Novartis’s New THERAPY

The Illumina, Inc. (NASDAQ:ILMN) request for dismissal in the patent lawsuit brought by Helicos BioSciences Corporation (HLCS) was granted; the litigation had been filed in October 2010. The judge decided that the patent was invalid because of an inadequate written description, and the sole remaining suit to be thrown out by the court, from three separate patents originally cited by Helicos in the lawsuit.

Don’t Miss: PANDORA: Leading the Way for Mobile Monetization.

Johnson & Johnson’s (NYSE:JNJ) Janssen Biotech division acquires worldwide licensing rights to the cancer agent daratumumab from Danish biotech Genmab, in a transaction potentially worth over $1.1 billion. Janssen will pay $55 million upfront and additional payments upon the achievement of development, regulatory and sales milestones. J&J is also buying an $80 million stake in Genmab.

Later in 2012, following the meeting of expectations on final trials, Novartis AG (NYSE:NVS) will file for Japanese and European Commission approval of QVA149, which is its therapy that integrates two of the firm’s other meds, and is used to treat smoker’s cough. On Wednesday, the FDA okayed a new dosage of Novartis’ cancer treatment Afinitor so it can be used by children suffering from a rare brain tumor.

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) reports that two papers have been published in the journal Cell, which show that single-stranded short interfering RNA molecules distributed broadly, activated the RNA interference pathway and selectively inhibit the expression of a targeted gene in animal models.

Don’t Miss: Time Warner Gears Up to Face Google.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.